PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Valneva shares positive chikungunya vaccine results

99% of participants retained very high neutralising antibody levels 12 months after treatment.

Valneva has announced positive antibody persistence data twelve months for its chikungunya vaccine candidate, VLA1553. Results from the single-dose vaccination have emerged 12 months after the treatment was administered.

The report follows positive safety and immunogenicity data during a phase 3 study of the therapy in March 2022. Meanwhile, Valneva also set up a dedicated antibody persistence trial to monitor a subset of participants for a period of at least five years to confirm the long-term durability of the antibody response after a single vaccination.

The antibody persistence trial enrolled 363 healthy adult participants and monitored them from month six after the vaccination to month 12. During this period, 99% of participants retained neutralising antibody levels above the seroresponse threshold of 150, 12 months after the single-dose vaccination.

These levels confirm the antibody persistence profile observed in an earlier study. The antibody persistence was similar in older adults aged over 65, who retained neutralising antibody titres comparable to younger adults.

There were no safety concerns identified for the duration of the follow-up study, confirming the safety profile observed across previous studies.

Juan Carlos Jaramillo, chief medical officer at Valneva, reflected: “We are excited about the twelve-month data which is in line with what we saw from our previous read out at month six, and strengthen the possibilities of inducing a long-lasting antibody response with our chikungunya vaccine candidate.”

“We are looking forward to completing the [Biologics License Application] BLA rolling submission to the [US Food and Drug Administration] FDA and potentially to changing people’s lives. If our investigational vaccine is approved, we are confident that it can help address this major, growing and unmet public health threat,” he added.

Valneva expects to finalise its BLA submission with the FDA by the end of the year.

Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus – a Togaviridae virus, transmitted by Aedes mosquitoes.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026